Norton Rose Fulbright represents Sanctum Therapeutics in merger with Adnexus Biotechnologies

A team of corporate and intellectual property lawyers from Norton Rose Fulbright represented Sanctum Therapeutics Corporation (Sanctum Therapeutics) in its merger transaction with Adnexus Biotechnologies Inc. (Adnexus). The combination is anticipated to accelerate the development of high-impact biotechnology therapies.

As a result of the merger transaction, Adnexus has acquired Sanctum Therapeutics and its core technology assets, including its long-acting HIV capsid inhibitor which can be used in conjunction with Adnexus’ short-acting anti-HIV monoclonal antibodies. This combination provides a promising new treatment option for HIV patients, offering a potent approach that enhances treatment efficacy and reduces the risk of viral resistance.

The acquisition also includes Sanctum Therapeutics’ SARS-CoV-2 entry inhibitor assets and technology in development at the Missouri Innovation Center, a non-profit organization focused on providing support for high growth business ventures that improve human life and sustainability, affiliated with the University of Missouri. Adnexus will continue advancing several innovative drugs using its state-of-the-art AI drug discovery and development platform.

Norton Rose Fulbright’s deal team was led by Kevin Friedmann and included Daniel Farris, Alex Katsulis (Chicago) and Adam Braun (St. Louis).